The IndiTreat® colorectal cancer (CRC) clinical trial is separated into two phases: a performance evaluation part and an interventional randomization part. The first part of the clinical study is getting close to a positive conclusion. The interim results, including 14 patients, show a 71% success rate with regard to preparation of 3D micro-tumors from needle biopsies of liver metastasis. Further, in all 3D micro-tumor preparations it has been possible to screen both standard and off-label treatments and provide a prioritizes list of treatments to the treating physician. With the present success rate, it is expected to enrol additional six patients before progressing into the randomized study. This randomized clinical study will randomize the patients into two groups, one where the IndiTreat results are being used to select patient treatment and one where the patients receive treatment according to the treating physicians’ best choice. As primary end-point the company will compare time to disease progression following treatment.
All patients enrolled in the IndiTreat® CRC clinical trial have late stage metastatic colorectal cancer and were progressing after two lines of standard treatments. Due to resistance towards standard treatments the company included off-label drugs meaning drugs that are approved for other cancer entities and not are part of CRC standard treatment regimens. The clinical trial is supported by a 3 MEUR grant from EU’s Horizon 2020 program.
“By running our first interventional trial in late stage metastatic CRC, we have put IndiTreat® to a tough test” says the CEO of 2cureX Ole Thastrup, and he continues “Since it has never before been tried to prepare 3D micro-tumors from needle biopsies of liver metastasis, it is a great pleasure to see that we have been able to do that with a 71% success rate. Further we have in some patients been able to identify alternative treatment options that goes beyond standard treatments. With the present positive clinical results our CRC clinical trial is progressing according to the previously presented plan”.
IndiTreat® has been developed by 2cureX in its laboratory facilities at hospitals in Copenhagen and in Hamburg. It is the expectation by 2cureX and its clinical partners that IndiTreat® will become a standard tool for the oncologists to choose the right treatment for the individual patient.
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 21th, 2018.
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).